Laurus Labs invests in Laurus Bio

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months

At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients

Increasing public awareness on World Zoonoses Day

India boasts the largest livestock population, with 536 million livestock and 851 million poultry

Healthcare Triangle completes US$2 million private placement debt offering

The company received gross proceeds of approximately US$1.7 million and net proceeds,

Inspira Technologies closes on $3.88 million RDO

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering

EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema

LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab

Moderna and Merck announce an investigational individualized neoantigen therapy

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients

Venus Remedies joins India AMR Innovation Hub

lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid